Immunovant (IMVT) Gains as Roivant Sciences Ltd. Explores Takeover
- U.S. stocks close down on news of Biden tax proposal
- Biden To Propose Capital Gains Tax As High As 43.4% For Wealthy - Bloomberg
- Intel (INTC) Tops Q1 EPS by 24c, Offers Guidance
- Snap (SNAP) Tops Q1 EPS by 5c, DAUs were 280 million, Offers Guidance
- Credit Suisse (CS) Falls 6% on 'Unacceptable Loss' as Exposure to Archegos Grew to More Than $20 Billion, Set to Raise Over $2 Billion to Support Liquidity
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Immunovant (NASDAQ: IMVT) gains 50% pre-open after Roivant Sciences Ltd. discloses in an amended 13D that it has engaged Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and SVB Leerink LLC to serve as its financial advisors in connection with the evaluation of a potential transaction involving the Issuer.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Zymergen (ZY) IPO Opens 30% Higher
- Discord walks away from Microsoft (MSFT) sale talks - WSJ
- Grubhub (GRUB) on Watch on Chatter
Create E-mail Alert Related Categories13Ds, Hot M&A, Mergers and Acquisitions, Rumors
Related EntitiesJPMorgan, Goldman Sachs, 13D, Pre Market Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!